Newsroom

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

PDF Version Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in 31 centers in both combination cataract and standalone...

read more +
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients

read more +
Sight Sciences Reports Second Quarter 2022 Financial Results

Sight Sciences Reports Second Quarter 2022 Financial Results   August 11, 2022 PDF Version   MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an...

read more +
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’...

read more +
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’...

read more +
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data

Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucoma. These 12-month outcomes were also confirmed by results from a subset of the study, assessing the Hispanic patient population

read more +
Sight Sciences Reports First Quarter 2022 Financial Results

Sight Sciences Reports First Quarter 2022 Financial Results   May 10, 2022 PDF Version   MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an...

read more +
Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended December 31, 2021.

read more +